Research programme: anticancer therapeutics - Tanox

Drug Profile

Research programme: anticancer therapeutics - Tanox

Alternative Names: Hodgkin's lymphoma therapy - Tanox; TNX 833

Latest Information Update: 10 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanox
  • Class Monoclonal antibodies
  • Mechanism of Action Cytokine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 03 Aug 2007 Tanox has been acquired by Genentech
  • 20 Dec 2005 Tanox has filed an IND with the FDA in USA for relapsed or refractory Hodgkin's lymphoma
  • 07 Nov 2005 Preclinical trials in Hodgkin's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top